前列腺活检推荐与接受中的偏倚显著影响前列腺癌风险因素评估:两项大型随机临床试验结果
研究基于两项前列腺癌预防试验(PCPT和SELECT)安慰剂组定期筛查男性,分析谁接受前列腺活检及活检验证对风险因素-前列腺癌关联的影响。结果显示年龄60-69岁、良性前列腺增生、家族史者更可能活检,而BMI≥25、糖尿病、吸烟史者更少活检;黑人与他族裔的OR在SELECT为1.20、PCPT为1.83,他汀使用OR在SELECT为0.65、PCPT为0.99(相对差异34%)。结论认为风险因素估计差异可能低估其他筛查和活检推荐及接受度不同队列中的偏倚程度,流行病学研究的风险因素可能错误并导致研究方向误导。
要点
- 年龄60-69岁、良性前列腺增生、前列腺癌家族史者更可能接受活检;BMI≥25、糖尿病、吸烟史者更少接受活检。
- 黑人相比其他族裔的OR在SELECT为1.20、PCPT为1.83;他汀使用OR在SELECT为0.65、PCPT为0.99,相对差异34%。
- 筛查和活检推荐及接受度的差异可能低估其他队列中的偏倚,流行病学风险因素可能错误并误导研究方向。
核心结论
- 在参加前列腺癌预防试验的筛查男性中,前列腺癌风险因素估计的差异可能低估了其他筛查和活检推荐及接受度不同队列中发现的偏倚程度。
- 来自流行病学研究的前列腺癌风险因素可能不仅错误,还可能导致研究方向误导。
研究设计与样本
- 研究检查了两项大型前列腺癌预防试验(PCPT和SELECT)安慰剂组中定期筛查的男性,以定义前列腺癌发病队列。
- PCPT有研究终点活检,前列腺癌病例按先前是否有前列腺特异性抗原/直肠指检提示(是/否)分类,非病例按活检证实阴性状态(是/否)分类。
- 研究估计了年龄、族裔、家族史、体重指数、药物使用等风险因素与前列腺癌的关联,并量化了不同队列间风险关联的差异。
主要发现
- 调整年龄和纵向前列腺特异性抗原及直肠指检后,60至69岁男性、良性前列腺增生者、有前列腺癌家族史者更可能接受活检,而体重指数较高(≥25)、糖尿病或吸烟史者更少接受活检。
- 药物使用、教育程度和婚姻状况也影响谁接受活检。
- 黑人(相比其他族裔)的比值比(OR)在SELECT为1.20,在PCPT为1.83。
- 他汀使用在SELECT的OR为0.65,在PCPT的OR为0.99,相对差异为34%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-of-study biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index (≥ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostate-specific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black ( v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplemented with imputed end points). Statin use in SELECT provided an OR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screened men enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts.
引用
- Tangen CM, Goodman PJ, Till C, et al. Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol. 2016. PMID: 27998216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。